Advertisement

Topics

Lundbeck Pharma A/S Company Profile

08:34 EST 10th December 2018 | BioPortfolio

Nil

Location

Dalbergstrøget 5
Taastrup
2630
Austria

Contact

Phone: 43 71 42 70
Fax: 43 71 42 74
Email: pharmainfo@lundbeck.com


News Articles [561 Associated News Articles listed on BioPortfolio]

Lundbeck brings third Parkinson's drug into clinic

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition. The comp...

VIDEO: Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO

Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she...   

#news #biotech After seeing POC data, Kyowa advances Parkinson’s program despite being dropped by Lundbeck 

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: After seeing POC data, Kyowa advances Parkinson’s program despite being dro...

Lundbeck Reaches Across Atlantic, Picks Dunsire for CEO Post

Deborah Dunsire, a veteran of Boston’s biotech scene, is taking off. Specifically, she’s taking the top job at Danish pharma firm Lundbeck, according to an announcement this morning. The m...

Otsuka, Lundbeck's Rxulti get positive opinion in EU from CHMP to treat schizophrenia in adults

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive...

Otsuka and Lundbeck report positive brexpiprazole results

Otsuka Pharmaceutical and Lundbeck have reported positive results from three Phase III studies evaluating the safety and efficacy of brexpiprazole...Read More... The post Otsuka and Lundbeck report po...

Lundbeck and Otsuka Announce Positive Phase 2 Data for Combination Treatment of Brexpiprazole and Sertraline in Post-Traumatic Stress Disorder

Valby, Denmark and Tokyo, Japan, 30 November 2018 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today the achievement of positive clinical results (in inte...

Deborah Dunsire Takes Over as CEO of Denmark’s H. Lundbeck

Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.

Drugs and Medications [253 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Multiple-therapy-resistant major depressive disorder: a clinically important concept.

SummaryMany novel therapeutic options for depression exist that are either not mentioned in clinical guidelines or recommended only for use in highly specialist services. The challenge faced by clinic...

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

Clinical Trials [86 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [794 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

LifeCycle Pharma

LifeCycle Pharma was founded in June 2002 as a spin-off from H. Lundbeck A/S. Its investors include H. Lundbeck A/S, Novo A/S, Nordic Biotech, Alta Partners (USA), and Adamant Biomedical Investments (...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...

Lundbeck Pharma A/S

Nil

Lundbeck

Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...

More Information about "Lundbeck Pharma A/S" on BioPortfolio

We have published hundreds of Lundbeck Pharma A/S news stories on BioPortfolio along with dozens of Lundbeck Pharma A/S Clinical Trials and PubMed Articles about Lundbeck Pharma A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck Pharma A/S Companies in our database. You can also find out about relevant Lundbeck Pharma A/S Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record